



LAWRENCE  
LIVERMORE  
NATIONAL  
LABORATORY

# Mechanism for Clastogenic Activity of Naphthalene

B. A. Buchholz

September 29, 2015

## **Disclaimer**

---

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

MILITARY INTERDEPARTMENT PURCHASE REQUEST: 10567486

TITLE: Mechanism for Clastogenic Activity of Naphthalene

PRINCIPAL INVESTIGATOR: Bruce A. Buchholz

CONTRACTING ORGANIZATION: Lawrence Livermore National Laboratory

REPORT DATE: September 25, 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

LLNL-TR-677645

## **Disclaimer**

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

## **Auspices Statement**

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 09/09/2015		2. REPORT TYPE Annual		3. DATES COVERED 1 Sep 2014- 31 Aug 2015	
4. TITLE AND SUBTITLE  Mechanism for Clastogenic Activity of Naphthalene				5a. CONTRACT NUMBER 10567486	
				5b. GRANT NUMBER LC130820	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Bruce A. Buchholz  E-Mail: buchholz2@llnl.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Lawrence Livermore National Lab 7000 East Avenue Livermore, CA 94550  UC Davis One Shields Avenue Davis, CA 95616				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Naphthalene incubations form DNA adducts in vitro in a dose dependent manner in both mouse and rat tissues. Rodent tissue incubations with naphthalene indicate that naphthalene forms as many DNA adducts as Benzo(a)pyrene, a known DNA binding carcinogen. The mouse airway has the greatest number of DNA adducts, corresponding to the higher metabolic activation of naphthalene in this location. Both rat tissues, the rat olfactory (tumor target) and the airways (non-tumor target), have similar levels of NA-DNA adducts, indicating that short term measures of initial adduct formation do not directly correlate with sites of tumor formation in the NTP bioassays.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  Unclassified	18. NUMBER OF PAGES  11	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  Unclassified	b. ABSTRACT  Unclassified	c. THIS PAGE  Unclassified			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>2</b>
<b>2. Keywords.....</b>	<b>2</b>
<b>3. Overall Project Summary.....</b>	<b>2</b>
<b>4. Key research Accomplishments.....</b>	<b>5</b>
<b>5. Conclusion.....</b>	<b>6</b>
<b>6. Publications, Abstracts, &amp; Presentations.....</b>	<b>6</b>
<b>7. Inventions, Patents, &amp; Licenses.....</b>	<b>6</b>
<b>8. Reportable Outcomes.....</b>	<b>6</b>
<b>9. Other Achievements.....</b>	<b>6</b>
<b>10. References.....</b>	<b>6</b>
<b>11. Appendix.....</b>	<b>7</b>

## 1. Introduction

There are two primary sources of naphthalene (NA) exposure to military personnel and to their families: the use of JP-8 as a common fuel for both aircraft and transport vehicles and mainstream and sidestream tobacco smoke. Jet fuels contain 1-3% naphthalene by weight, DoD uses an estimated 5.5 billion gallons of JP-8 annually. Naphthalene is the single most prevalent aromatic hydrocarbon in second hand smoke exceeding the levels of polycyclic aromatic hydrocarbons like benzo(a)pyrene (BaP) nearly 250 fold (Witschi et al, Carcinogenesis 18, 2035, 1997). The EPA has listed NA as a probable human carcinogen based on the results of the cancer bioassay conducted in both mice and rats. However, there are many groups arguing that NA-induced respiratory tumors in rodents are not relevant to estimating the risks to exposed human populations (see Piccirillo et al, Regul Toxicol Pharmacol. 62: 433, 2012) based on the much slower rates of microsomal NA metabolism in primate compared to rodent respiratory tissue, on the finding that NA is not mutagenic in most *in vitro* short term assays and on epidemiologic data showing that nasal tumors in humans are very rare. This work is intended to provide solid evidence for or against a clastogenic mechanism of action for NA in rodent and non-human primate respiratory tissues. Determining the ability of fresh non-human primate tissues to generate NA metabolites that bind to DNA using ultrasensitive and highly specific assays would provide a mechanistic basis for assessing the risks of NA exposure. If these studies demonstrate binding of metabolites generated in primate tissues to DNA, either removal of NA from fuel sources or additional engineering controls could be established to further protect personnel.

## 2. Keywords

naphthalene, DNA adducts, clastogen, metabolite

## 3. Overall Project Summary

All IACUC and ACURO approvals were obtained quickly at the start of project and the subcontract between LLNL and UC Davis (UCD) was executed at the start of December 2014. During the reporting period all the rodent exposures were completed. Rhesus monkey exposures on animals culled from the colony at the UCD California National Primate Research Center (CNPRC) need to be conducted during the fall of 2015.

As proposed, all *in vitro* exposures were conducted using fresh micro-dissected tissues obtained at UCD as described in Van Winkle et al (1996). Tissues were incubated with 2.5, 25, or 250  $\mu\text{M}$   $^{14}\text{C}$ -NA, 25 or 50  $\mu\text{M}$   $^{14}\text{C}$ -benzo(a)pyrene (BaP), or unlabeled sham controls. The groups were treated with NA at 250 and 2.5  $\mu\text{M}$  to test the upper and lower limits of exposure based on John Morris' published (2012) calculations of an upper limit for delivered dose at 250  $\mu\text{M}$  as equivalent to the 10 ppm OSHA exposure limit for NA. Tissues were incubated for 60 minutes followed by 12-15 rinses with ethanol to remove unbound NA or BaP. Tissues were rinsed until the rinse no longer had excess  $^{14}\text{C}$ . DNA was isolated from tissues with Qiagen DNeasy kits according to the manufacturer protocols with modification. Two proteinase K digestions were done to assure complete removal of protein. DNA purity was assessed using UV absorbance at 260/280 nm. DNA samples were then prepared for graphitic carbon  $^{14}\text{C}$ -AMS analyses using standard procedures (Ognibene et al, 2003; Ognibene et al, 2015a). The NA-DNA adduct levels are depicted in Figures 1-4.




Figure 1. Adducts of BaP or NA per genome in mouse airway. Six replicates were prepared for each dose group with one sample failure at the 250  $\mu$ M NA and two sample failures at the 2.5  $\mu$ M NA dose. The average is shown for each dose group.




Figure 2. Adducts of BaP and NA per genome in rat airway. Six replicates were prepared and the average is shown for each dose group.






Figure 3. Adducts of BaP and NA per genome in rat olfactory tissue. Six replicates were prepared for each dose group with one sample failure at each the 25  $\mu$ M BaP and the 2.5  $\mu$ M NA dose. The average is shown for each dose group.




Figure 4. Adducts of BaP and NA per genome in rat respiratory tissue. Six replicates were prepared and the average is shown for each dose group.

Based on the National Toxicology Program (NTP) carcinogenesis bioassays (North et al, 2008), we expected to see the highest level of NA-DNA adducts correspond to the recorded cancer sites following NA exposures: bronchiolar alveolar carcinomas in the airways of female mice and neuroblastomas in the nasal epithelium of rats. Instead, we found the highest measured frequency of NA-DNA adducts in mouse airway, followed by rat airway. Rat olfactory tissue had low levels of adducts similar to rat respiratory tissue. Rat airway did not develop tumors in the NTP bioassay (North et al, 2008). Our experiments did not examine adduct stability, only whether adducts formed upon exposure.

The experiments aimed at determining which DNA bases were adducted by specific NA metabolites have been more difficult to complete than anticipated. Producing adducted nucleosides of NA metabolites has been slowed by the inability to obtain all the reactive NA metabolites. Our original plan was to perform *in vitro* exposures and purify DNA as described above, followed by DNA digestion and HPLC separation of adducted bases followed by AMS analyses of collected fractions (Buchholz et al, 1999). Adducted bases would be identified by co-chromatography with synthetic standards. During the summer of 2015 LLNL acquired a Waters Xevo G2 XS QTOF instrument for qualitative and quantitative sample analysis that has been installed with the new liquid sample AMS interface ((Ognibene et al, 2015b). The QTOF enables accurate mass analyses for a variety of analytical applications, including metabolite profiling, identification, characterization, and quantification of both small and macromolecules. The QTOF is coupled to a Waters Acquity H Class HPLC system used to separate samples for introduction to the liquid sample AMS interface. A flow splitter is configured such that eluent from the HPLC flows to the QTOF for qualitative and quantitative analysis, and to the AMS instrument for isotope ratio measurement. Mass spectra are aligned based on retention times to match AMS results to mass spectrometric analytes. Coupling QTOF and AMS measurements in this way constitutes a powerful improvement to our analytical capabilities since molecular ion mass will identify the analyte and AMS will quantify the adduct level. We anticipate completion of the metabolite-adduct experiments by winter.

#### **4. Key Research Accomplishments**

The key research accomplishments to date from the quantitation of NA-DNA adducts in mouse and rat tissues are the following:

- Naphthalene incubations form DNA adducts in a dose dependent manner in both mouse and rat tissues
- Rodent tissue incubations with naphthalene indicate that naphthalene forms as many DNA adducts as Benzo(a)pyrene, a known DNA binding carcinogen, acutely.
- The mouse airway has the greatest number of DNA adducts, corresponding to the higher metabolic activation of naphthalene in this location.
- Both rat tissues, the rat olfactory (tumor target) and the airways (non-tumor target), have similar levels of NA-DNA adducts, indicating that short term measures of initial adduct formation do not directly correlate with sites of tumor formation in the NTP bioassays.

## 5. Conclusion

The NTP bioassays following NA exposure produced neuroblastomas in the nasal epithelium of rats while rat airways did not grow tumors. If the number of initial NA-DNA adducts was the single key event in determining tumor formation at these sites we would expect more adducts in the rat olfactory epithelium than in the rat airway. However, our data indicates slightly higher formation of adducts in rat airway than rat olfactory tissues. Our experiments quantified NA-DNA adduct formation, but did not assess adduct stability. The lack of tumors in the rat airway of the NTP bioassays suggests the adducts we measured are not stable in the long term and are cleared shortly after formation. Furthermore, the high level of NA-DNA adducts we measured in mouse airway were 60-300x that measured in rat tissues at the 250  $\mu$ M exposure. Yet, the NTP bioassays found rat nasal tumors more prevalent than mouse airway tumors. It appears as though the airway tissues clear a significant amount of NA-DNA adducts *in vivo*. The rhesus monkey tissue exposures planned for fall 2015 will hopefully help put the rodent studies in context. Also the planned adduct-nucleoside separations may shed some light on adduct stability. It is likely that some of the adducts will not be stable following DNA digestion and nucleoside separation.

## 6. Publications, Abstracts, & Presentations

An abstract is being submitted to the Society of Toxicology Meeting for spring 2016.

## 7. Inventions, Patents, & Licenses

None.

## 8. Reportable Outcomes

None at this time.

## 9. Other Achievements

None.

## 10. References

Buchholz BA, Fultz E, Haack KW, Vogel JS, Gilman SD, Gee SJ, Hammock BD, Hui X, West RC, Maibach HI (1999) HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. *Anal Chem* **71**(6): 3519-3525.

Morris JB (2012) Biologically-based modeling insights in inhaled vapor absorption and dosimetry. *Pharmacology & Therapeutics* **136**(3): 401-413.

North DW, Abdo KM, Benson JM, Dahl AR, Morris JB, Renne R, Witschi H (2008). A review of whole animal bioassays of the carcinogenic potential of NA. *Regul Toxicol & Pharmacol* **51**: S6-14. DOI: 10.1016/j.yrtph.2007.09.022

Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S (2003) A high-throughput method for the conversion of CO<sub>2</sub> obtained from biochemical samples to graphite in septa-sealed vials for quantification of <sup>14</sup>C via accelerator mass spectrometry. *Anal Chem* **75**(9): 2192-2196.

Ognibene TJ, Haack KW, Bench G, Brown TA, Turteltaub KW (2015a) Operation of the “Small” BioAMS spectrometers at CAMS: Past and future prospects. *Nucl. Instr. Meth. B* [Epub ahead of print 26 May 2015] doi:10.1016/j.nimb.2015.05.019

Ognibene TJ, Thomas AT, Daley PF, Bench G, Turteltaub KW (2015b) An interface for the direct coupling of small liquid samples to AMS. *Nucl. Instr. Meth. B* [Epub ahead of print 28 May 2015] doi:10.1016/j.nimb.2015.05.018

Piccirillo VJ, Bird MG, Lewis RJ, Boyer WJ (2012) Preliminary evaluation of the human relevance of respiratory tumors observed in rodents exposed to naphthalene. *Regul Toxicol Pharmacol* **62(3)**: 433-440.

Van Winkle LS, Buckpitt AR, Plopper CG (1996) Maintenance of differentiated murine Clara cells in microdissected airway cultures. *Am J Respir Cell Mol Biol* **14(6)**: 586-598.

Witschi, H, Espirit, I, Maronpot RR, Pinkerton KE, Jones AD (1997) The carcinogenic potential of the gas phase of environmental tobacco smoke. *Carcinogenesis* **18(11)**: 2035-2042.

## **11. Appendices**

Quad chart attached.

# Mechanism for Clastogenic Activity of Naphthalene

LC130820

MIPR:10567486



PI: Bruce Buchholz

Org: Lawrence Livermore National Laboratory


Award Amount: \$165K

## Study/Product Aim(s)

- Identify the types of adducts naphthalene (NA) forms with DNA
- Determine whether adduct formation correlates with site selective tumor formation in defined subcompartments of the respiratory tract

## Approach

The location of lung and nasal tumors in rodents exposed to NA are highly specific to defined regions within the respiratory tract. We will utilize microdissection methods to isolate live tissue from these target areas. This approach combined with accelerator mass spectrometry (AMS) will determine whether DNA adducts are formed in the target tissue following incubation with <sup>14</sup>C-NA.



Determine if naphthalene (NA) in jet fuel and cigarette smoke forms DNA adducts that can lead to cancer in respiratory tissues

Accomplishment: Rodent in vitro exposures complete. Acquisition NA metabolites and generation of adducted DNA bases for HPLC underway.

## Timeline and Cost

Activities	CY	14	15
Animal Protocol & Contract Complete		<div><div></div></div>	
In Vitro Studies for Aim 1 Complete		<div><div></div></div>	<div><div></div></div>
In Vitro Studies for Aim 2 Complete		<div><div></div></div>	<div><div></div></div>
Sample Analyses Complete		<div><div></div></div>	<div><div></div></div>
Data Analyses and Reporting		<div><div></div></div>	<div><div></div></div>
Estimated Budget (\$K)		\$15	\$150

Updated: (15-September-2015)

## Goals/Milestones

**Q1 Goals** – Approval of Animal Protocol and Subcontract Executed

- ☒ Animal protocols approved
- ☒ Subcontract with UCD executed

**Q2 Goal** – Begin Experimental Work

- ☒ Begin in vitro studies and sample analyses for aims 1& 2

**Q3 Goal** – Complete Experimental Work

- ☐ Finish all in vitro studies and sample analyses

**Q4 Goals** – Complete Data Analyses and Reporting

- ☐ Complete and submit peer-reviewed publication
- ☐ Complete and submit final report

## Comments/Challenges/Issues/Concerns

- Monkey in vitro exposures to be completed fall 2015.
- Delay in securing metabolite adducted bases has HPLC work for Goal 1 behind schedule.

## Budget Expenditure to Date

Projected Expenditure: \$165K

Actual Expenditure: \$100K